A PYMNTS Company

US: Pharma merger breezes through review

By  |  December 13, 2013

Pharmaceutical company Shire announced that it has been given clearance for its acquisition of ViroPharma Incorporated, a deal previously announced.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Shire announced Friday the expiration of the Hart-Scott-Rodino Act’s merger waiting period, though reports say the deal must meet certain requirements to finalize.

    Should the deal go through, however, Shire is set to make the acquisition for about $4.2 billion. The strategic buyout would allow the company to broaden its rare disease treatment portfolio.

    Full Content: Zacks

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.